To confirm the advantage of in situ reconstruction (ISR) over extra-anatomic reconstruction (EAR) for aortic graft infection and determine the most appropriate conduit including autogenous veins, cryopreserved allografts, and synthetic prosthesis (standard, rifampicin of silver polyesters).
Methods:
A meta-analysis was conducted with rate of mortality, graft occlusion, amputation, and reinfection. A meta-regression was performed with 4 factors: patients’ age, presence of prosthetic-duodenal fistula (PDF), virulent organisms, or nonvirulent organisms.
Results:
In situ reconstruction over EAR seems to favor all events. For the 5 conduits used for ISR, according to operative mortality, age of the patients looks to have a positive correlation only for silver polyester and no conduit present any advantage in the presence of PDF. Reinfection seems to be not significantly different for the 5 conduits, and only autogenous veins appear to have a positive correlation with infecting organisms.
Conclusion:
In situ reconstruction may be considered as first-line treatment. Our results suggest that silver polyesters appear to be most appropriate for older patients, and in order to limit reinfection, autogenous veins are probably the most suitable conduit.
HalletJWJrMarshallDMPettersonTM. Graft-related complications after abdominal aortic aneurysm repair: reassurance from a 36-year population-based experience. J Vasc Surg. 1997;25(2):277–284; discussion 285-286.
2.
KitamuraTMorotaTMotomuraN. Management of infected grafts and aneurysms of the aorta. Ann Vasc Surg. 2005;19(3):335–342.
3.
BergerPVaartjesIMollFLDeBorstBlankensteijnJDBostML. Cumulative incidence of graft infection after primary prosthetic aortic reconstruction in the endovascular era. Eur J Vasc Endovasc Surg. 2015;49(5):581–585.
4.
BattMJean-BaptisteEO’ConnorSFeugierPHaulonS; Association Universitaire de Recherche en Chirurgie Vasculaire (AURC). Contemporary management of infrarenal aortic graft infection: early and late results in 82 patients. Vascular. 2012;20(3):129–137.
5.
ArmstrongPABackMRWilsonJSShamesMLJohnsonBLBandykDF. Improved outcomes in the recent management of secondary prosthetic-duodenal fistulae. J Vasc Surg. 2005;42(4):660–666.
6.
OderichGSBowerTCCherryKJ. Evolution from axillofemoral to in situ prosthetic reconstruction for the treatment of aortic graft infections at a single center. J Vasc Surg. 2006;43(6):1166–1174.
7.
LyonsOTAPatelASSahaASCloughREPriceNTaylorPR. A 14 year experience with endograft infection: management and results. Eur J Vasc Endovasc Surg. 2013;46(3):306–313.
8.
NoelAAGloviczkiPCherryKJ. Abdominal aortic reconstruction in infected fields: early results of the United States cryopreserved aortic allograft registry. J Vasc Surg. 2002;35(5):847–852.
9.
O’ConnorSAndrewPBattMBecqueminJP. A systematic review and meta-analysis of treatment for aortic graft infection. J Vasc Surg. 2006;44(1):38–45.
10.
VerhelstRLacroixVVrauxH. Use of cryopreserved arterial homografts for management of infected prosthetic grafts: a multi-center study. Ann Vasc Surg. 2000;14(6):602–607.
11.
AliATModrallJGHockingJ. Long-term results of the treatment of aortic graft infection by in situ replacement with femoral popliteal vein grafts. J Vasc Surg. 2009;50(1):30–39.
12.
KiefferEGomesDChicheLFleronMHKoskasFBahniniA. Allograft replacement for aortic graft infection: early and late results in 179 patients. J Vasc Surg. 2004;39(5):1009–1017.
13.
YoungRMCherryKJDavisPM. The results of in situ prosthetic replacement for infected aortic grafts. Am J Surg. 1999;178(2):136–140.
14.
PupkaASkoraJJanczakDPlonekTMarczakJSzydelkoT. In situ revascularization with silver-coated polyester prostheses and arterial homografts in patients with aortic graft infection—a prospective, comparative, single-centre study. Eur J Vasc Endovasc Surg. 2011;41(1):61–67.
15.
MoherDLiberatiATetzlaffJAltmanDG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341.
16.
TeebkenOEBisdasTAssadianORiccoJB. Recommendations for reporting treatment of aortic graft infections. Eur J Vasc Endovasc Surg. 2012;43(2):174–181.
17.
BermanNGParkerRA. Meta-analysis: neither quick nor easy. BMC Med Res Methodol. 2002;2:10.
18.
SharpWJHoballahJJMohanCR. The management of the infected aortic prosthesis: a current decade of experience. J Vasc Surg. 1994;19(5):844–850.
19.
KuestnerLMReillyLMJichaDLEhrenfeldWKGoldstoneJStoneyRJ. Secondary prosthetic-duodenal fistula: Contemporary outcome with use of extra-anatomic bypass and infected graft excision. J Vasc Surg. 1995;21(2):184–196.
20.
HannonRJWolfeJHNMansfieldAO. Aortic prosthetic infection: 50 patients treated by radical or local surgery. Br J Surg. 1996;83(5):654–658.
21.
BergqvistDBjörkmanHBolinT. Secondary prosthetic-duodenal fistulae—changes from 1973 to 1993. Eur J Vasc Endovasc Surg. 1996;11(4):425–428.
SpezialeFRizzoLSbarigiaE. Bacterial and clinical criteria relating to the outcome of patients undergoing in situ replacement of infected abdominal aortic grafts. Eur J Vasc Endovasc Surg. 1997;13(2):127–133.
25.
BelairMSoulezGOlivaVL. Aortic graft infection: the value of percutaneous drainage. AJR Am J Roentgenol. 1998;171(1):119–124.
26.
EugèneMGerotaJ. Cryopreserved aortic allograft replacement of infected prosthetic graft in man: processing and clinical results. Transpl Int. 1998;11(suppl 1):S452–S454.
27.
HayesPDNasimALondonNJM. In situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience (1992 to 1998). J Vasc Surg. 1999;30(1):92–98.
28.
SeegerJMPretusHAWelbornMBOzakiCKFlynnTCHuberTS. Long-term outcome after treatment of aortic graft infection with staged extra-anatomic bypass grafting and graft removal. J Vasc Surg. 2000;32(3):451–461.
29.
BandykDFNovotneyMLBackMRJohnsonBJSchmachtDC. Expanded application of in situ replacement for prosthetic graft infection. J Vasc Surg. 2001;34(3):411–420.
CardozoMAFrankiniADBonamigoTP. Use of superficial femoral vein in the treatment of infected aortoiliofemoral prosthetic grafts. Cardiovasc Surg. 2002;10(4):304–310.
32.
DorigoWPulliRAzasLPratesiGInnocentiAAPratesiC. Early and long-term results of conventional surgical treatment of secondary aorto-enteric fistula. Eur J Vasc Endovasc Surg. 2003;26(5):512–518.
33.
LavigneJPPostalAKohlPLimetR. Prosthetic vascular infection complicated or not by prosthetic-duodenal fistula: comparison of treatment with and without cryopreserved allograft (homografts). Eur J Vasc Endovasc Surg. 2003;25(5):416–423.
34.
DaenensKFourneauINevelsteenA. Ten-year experience in autogenous reconstruction with the femoral vein in the treatment of aortofemoral prosthetic infection. Eur J Vasc Endovasc Surg. 2003;25(3):240–245.
35.
BattMMagneJLAlricP. In situ revascularization with silver-coated polyester grafts to treat aortic infection: early and midterm results. J Vasc Surg. 2003;38(5):983–989.
36.
GabrielMPukackiFDzieciuchowiczLOszkinisGChecinskiP. Cryopreserved arterial allografts in the treatment of prosthetic graft infections. Eur J Vasc Endovasc Surg. 2004;27(6):590–596.
37.
HartJPEgintonMTBrownKR. Operative strategies in aortic graft infections: is complete graft excision always necessary?Ann Vasc Surg. 2005;19(2):154–160.
38.
BarilDTCarroccioAEllozySH. Evolving strategies for the treatment of prosthetic-duodenal fistulas. J Vasc Surg. 2006;44(2):250–257.
39.
MirzaieMSchmittoJDFatehpurS. Surgical management of vascular graft infection in severely ill patients by partial resection of the infected prosthesis. Eur J Vasc Endovasc Surg. 2007;33(5):610–613.
40.
BattMJean-BaptisteEO’ConnorS. In situ revascularisation for patients with aortic graft infection: a single-centre experience with silver-coated polyester grafts. Eur J Vasc Endovasc Surg. 2008;36(2):182–188.
41.
AavikALiebergJKalsJPulgesAKalsMLepnerU. Ten years experience of treating aorto-femoral bypass graft infection with venous allografts. Eur J Vasc Endovasc Surg. 2008;36(4):432–437.
42.
Harlander-LockeMPHarmonLKLawrencePF. The use of cryopreserved aortoiliac allograft for aortic reconstruction in the United States. J Vasc Surg. 2014;59(3):669–674.
Charlton-OuwKMSandhuHKHuangG. Reinfection after resection and revascularization of infected infrarenal abdominal aortic grafts. J Vasc Surg. 2014;59(3):684–692.
45.
ToumaJCochennecFParisotJ. In situ reconstruction in native and prosthetic aortic infections using cryopreserved arterial allografts. J Vasc Endovasc Surg. 2014;48(3):292–299.
46.
BattMJean BaptisteEO’ConnorS. Early and late results of contemporary management of 37 secondary prosthetic-duodenal fistulae. Eur J Vasc Endovasc Surg. 2011;41(6):748–757.
47.
BisdasTWilhelmiMHaverichATeebkenOE. Cryopreserved arterial homografts vs silver-coated Dacron for abdominal aortic infections with intra-operative evidence of microorganisms. J Vasc Surg. 2011;53(5):1274–1281.
48.
EarnshawJJ. The current role of Rifampicin-impregnated grafts: pragmatism versus science. Eur J Vasc Endovasc Surg. 2000;20(5):409–412.
49.
NaylorAR. Limitations in the use of rifampicin-gelatin grafts against virulent organisms. J Vasc Surg. 2002;35(4):823–824.
50.
BandykDFNovotneyMLJohnsonBLBackMRRothSR. Use of rifampicin-soaked gelatin-sealed polyester grafts for in situ treatment of primary aortic and vascular prosthetic infections. J Surg Res. 2001;95(1):44–49.
51.
ColburnMDMooreWSChvapilMGelabertHAQuioñones-BaldrichWJ. Use of an antibiotic-bonded graft for in situ reconstruction after prosthetic graft infections. J Vasc Surg. 1992;16(4):651–660.
52.
Gordon LL HaginoRTJacksonMRModrallGValentineRJClagettP. Complex aortofemoral prosthetic infections. The role of autogenous superficial femoro-popliteal vein reconstruction. Arch Surg. 1999;134(6):615–621.
53.
EhsanOGibbonsCP. A 10-year experience of using femoro-popliteal vein for re-vascularisation in graft and arterial infections. Eur J Vasc Endovasc Surg. 2009;38(2):173–179.
54.
DorweilerBNeufangAChabanRReinstadlerJDuenschedeFVahlCF. Use and durability of femoral vein for autologous reconstruction with infection of the aortoiliofemoral axis. J Vasc Surg. 2014;59(3):675–683.
55.
ClagettGPValentineRJHaginoRT. Autogenous aortoiliac/femoral reconstruction from superficial femoro-popliteal veins: feasibility and durability. J Vasc Surg. 1997;25(2):255–270.
56.
BoyleJR. Superficial femoral vein is superior to cryopreserved allografts for in situ aortic reconstruction. Eur J Vasc Endovasc Surg. 2014;48(3):300.
57.
SöreliusKManiKBjörckM. Endovascular treatment of mycotic aneurysms: a European multicenter study. Circulation. 2014;130(24):2136–2142.
58.
OderichGSPannetonJMBowerTC. Infected aortic aneurysms: aggressive presentation, complicated early outcome, but durable results. J Vasc Surg. 2001;34(5):900–908.
59.
PetittiDB. Approaches to heterogeneity in meta-analysis. Stat Med. 2001;20(23):3625–3633.
60.
RevestMCamouFSennevilleE. Medical treatment of prosthetic vascular graft infections: review of the literature and proposals of a working group. Int J Antimicrob Agents. 2015;46(3):254–265.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
